QC
RLMD icon

Quadrature Capital’s Relmada Therapeutics RLMD Stock Holding History

Quadrature Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87K Sell
12,498
-40,946
-77% -$194K ﹤0.01% 1239
2025
Q4 		$258K Buy
+53,444
New +$179K ﹤0.01% 894

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Quadrature Capital's RLMD Position: Q1 2026 in Review

Quadrature Capital reduced its Relmada Therapeutics (RLMD) stake by 77% in Q1 2026, selling an estimated $194K and leaving 12,498 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Quadrature Capital first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $258K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Quadrature Capital held 12,498 shares of Relmada Therapeutics worth $87K as of Q1 2026.
  • Quadrature Capital sold 40,946 Relmada Therapeutics shares in Q1 2026, an estimated $194K.
  • Relmada Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1239 holding.
  • Quadrature Capital first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Relmada Therapeutics position peaked at $258K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.